Literature DB >> 16036012

Unattended home sleep studies for the evaluation of suspected obstructive sleep apnoea syndrome in children.

Amit Patel1, Mando Watson, Parviz Habibi.   

Abstract

Children suspected of obstructive sleep apnoea syndrome (OSAS) are traditionally investigated in hospital with overnight sleep studies, and single-channel pulse oximetry is the commonest form of initial study. A prospective study was conducted comparing unsupervised sleep studies, using a Nellcor N-395 pulse oximeter, performed in hospital and at home. Two hundred and eleven patient studies were completed in 18 months, 158 in hospital and 53 at home. The median age of patients was four years in both groups. The mean study duration was 9 h 5 min in hospital and 9 h 12 min at home (P = 0.75). The mean time in pulse search was 0.4% (SD = 0.7) in hospital and 0.2% (SD = 0.4) at home (P = 0.008). The number of failed studies was 96 of 254 (38%) in hospital and three of 56 (5%) at home (P < 0.001). Overall, 149 hospital bed days were saved (at pounds 690 per bed day), representing pounds 68,540 saved annually. The results show that unattended home sleep studies in the form of overnight pulse oximetry can be performed to a standard better than hospital studies, where local community nursing facilities exist.

Entities:  

Mesh:

Year:  2005        PMID: 16036012     DOI: 10.1258/1357633054461570

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  2 in total

Review 1.  Cutting-edge technologies for diagnosis and monitoring of snoring in children.

Authors:  Ioannis Vlastos; Ioannis Athanasopoulos
Journal:  World J Clin Pediatr       Date:  2016-02-08

2.  Comparison of home ambulatory type 2 polysomnography with a portable monitoring device and in-laboratory type 1 polysomnography for the diagnosis of obstructive sleep apnea in children.

Authors:  Adelaide Withers; Jennifer Maul; Ellen Rosenheim; Anne O'Donnell; Andrew Wilson; Stephen Stick
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.